People · Operator
Named in public records as an officer, director or promoter · active 2009–2010 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| iPierian, Inc. | — | Pharmaceuticals | Series B | $87.3M | $985.1M | 2010 |
| Pervasis Therapeutics Inc | — | Biotechnology | Series A | $10.0M | $361.6M | 2009 |
| Helicos Biosciences Corp | — | Biotechnology | Series A | $10.0M | $361.5M | 2009 |
Robert F Higgins at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert F Higgins on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John Walker | 1 | 17 |
| Beth Seidenberg | 1 | 15 |
| Amir Nashat | 1 | 14 |
| Robert S Langer | 1 | 14 |
| Corey Goodman | 1 | 13 |
| Brian G. Atwood | 1 | 8 |
| Noubar B Afeyan | 1 | 5 |
| Corey S. Goodman | 1 | 4 |
| Stanley N. Lapidus | 1 | 4 |
| Beth F. Seidenberg | 1 | 4 |
| Frank Litvack | 1 | 3 |
| EDWIN M. KANIA | 1 | 3 |
| Earl M Collier | 1 | 3 |
| Berta Strulovici | 1 | 2 |
| Bob Higgins | 1 | 2 |
| Elazer R Edelman | 1 | 2 |
| Matthew J. Plunkett | 1 | 2 |
| Michael Venuti | 1 | 2 |
| RONALD A. LOWRY | 1 | 1 |
| Helen M Nugent | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.